Literature DB >> 7398728

Amiodarone-induced ventricular fibrillation.

J M McComb, K R Logan, M M Khan, J S Geddes, A A Adgey.   

Abstract

Amiodarone, 600 mg orally daily, was used in an attempt to control supraventricular tachyarrhythmias in a patient with the sick sinus syndrome. Twenty days from the onset of therapy the Q-T interval lengthened. Episodes of ventricular flutter, ventricular fibrillation and self-terminating ventricular tachyarrhythmia (torsade de pointes) developed on the 28th day of amiodarone therapy. Temporary cardiac pacing prevented further episodes of ventricular fibrillation. Despite the suggestion that this drug may be given in large doses for long periods of time since it has a wide safety margin, we feel that the risk of lethal arrhythmias is such that caution is required in its use.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7398728

Source DB:  PubMed          Journal:  Eur J Cardiol        ISSN: 0301-4711


  12 in total

1.  Effects of bepridil on ventricular depolarization and repolarization of rabbit isolated hearts with particular reference to its possible proarrhythmic properties.

Authors:  T Osaka; I Kodama; J Toyama; K Yamada
Journal:  Br J Pharmacol       Date:  1988-04       Impact factor: 8.739

2.  Prolonged Q-T interval and severe tachyarrhythmias, common features of sotalol intoxication.

Authors:  P J Neuvonen; E Elonen; T Vuorenmaa; M Laakso
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

3.  Comparison of acute electrophysiological effects of amiodarone and its metabolite desethylamiodarone in Langendorff perfused guinea pig hearts.

Authors:  G Stark; U Stark; M Windisch; M Vicenzi; U Eggenreich; S Nagl; K Kral; E Pilger; H A Tritthart
Journal:  Basic Res Cardiol       Date:  1991 Mar-Apr       Impact factor: 17.165

4.  Electrophysiological effects of sotalol--just another beta blocker?

Authors:  A W Nathan; K J Hellestrand; R S Bexton; D E Ward; R A Spurrell; A J Camm
Journal:  Br Heart J       Date:  1982-06

5.  Electrophysiologic testing: predictive of amiodarone efficacy in recurrent sustained ventricular tachycardia?

Authors:  I J Mas; A Massumi; M Harlan; J J Seger; R J Hall
Journal:  Tex Heart Inst J       Date:  1987-12

Review 6.  Class III antiarrhythmics in overdose. Presenting features and management principles.

Authors:  E W Leatham; D W Holt; W J McKenna
Journal:  Drug Saf       Date:  1993-12       Impact factor: 5.606

Review 7.  Torsades de pointes: prevention and therapy.

Authors:  A Keren; D Tzivoni
Journal:  Cardiovasc Drugs Ther       Date:  1991-04       Impact factor: 3.727

Review 8.  QT-interval prolonging drugs: mechanisms and clinical relevance of their arrhythmogenic hazards.

Authors:  M Zehender; S Hohnloser; H Just
Journal:  Cardiovasc Drugs Ther       Date:  1991-04       Impact factor: 3.727

Review 9.  Drug-induced torsade de pointes. Incidence, management and prevention.

Authors:  T S Faber; M Zehender; H Just
Journal:  Drug Saf       Date:  1994-12       Impact factor: 5.606

10.  Amiodarone-treated patients with suppressed TSH test are at risk of thyrotoxicosis.

Authors:  M Stäubli; H Studer
Journal:  Klin Wochenschr       Date:  1985-02-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.